Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation

Table 3 Results representing the Cell cycle analysis of MFX and CFX treated Panc-1 cells

24 h	Sub G1	G1	S	G2	48 h	Sub G1	G1	S	G2
Panc-1	Sub G1	G1	S	G2	Panc-1	Sub G1	G1	S	G2
0 μg/ml	4.8 ± 1.5	61.6 ± 0.5	7.8 ± 0.7	25.8 ± 0.9	0 μg/ml	4.1 ± 0.8	66.2 ± 1	7.3 ± 0.5	22.4 ± 1.5
MFX 100 μg/ml	4.4 ± 1	59.7 ± 2	9.7 ± 1	26.2 ± 2	MFX 100 μg/ml	4 ± 0.5	56.7 ± 2.4	10.8 ± 1.5	28.5 ± 1
MFX 200 μg/ml	5.6 ± 1.2	60.2 ± 1.2	11.6 ± 1.3	22.6 ± 1.4	MFX 200 μg/ml	4.1 ± 1	50.3 ± 3.1	20.6 ± 2	24.6 ± 0.8
MFX 400 μg/ml	10.4 ± 1 %	57.9 ± 2.5	7.1 ± 0.6	24.6 ± 1.5	MFX 400 μg/ml	20.5 ± 2.5	52.8 ± 1.9	12.4 ± 1	14.3 ± 2.2
CFX 100 μg/ml	5.1 ± 0.8	61 ± 1.3	8.4 ± 1	25.5 ± 0.5	CFX 100 μg/ml	4.2 ± 1.1	53.6 ± 1.2	13.4 ± 1.5	28.8 ± 1.7
CFX 200 μg/ml	24 ± 1.2	51 ± 2.1	9 ± 0.5	16 ± 1.6	CFX 200 μg/ml	17.7 ± 2	50.2 ± 2.4	10.6 ± 1.1	21.5 ± 0.9
CFX 400 μg/ml	32 ± 1.5	48.2 ± 3.2	7.3 ± 1	12.5 ± 2	CFX 400 μg/ml	54.4 ± 1.5	28.9 ± 3.3	8.1 ± 0.8	8.6 ± 2.6

Values represent the percent of population in each phase. Values with significant changes have been highlighted with bold format

ISSN: 1471-2407